MX2020014303A - Inhibición de la proteína de union a creb (cbp). - Google Patents

Inhibición de la proteína de union a creb (cbp).

Info

Publication number
MX2020014303A
MX2020014303A MX2020014303A MX2020014303A MX2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A
Authority
MX
Mexico
Prior art keywords
cbp
binding protein
bromodomains
family
creb binding
Prior art date
Application number
MX2020014303A
Other languages
English (en)
Inventor
Torsten Herbertz
Anna Ericsson
Hongbin Li
Steven Mischke
Shawn E R Schiller
Bradford Graves
Angela V West
Jennifer R Downing
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051235 external-priority patent/WO2019055877A1/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2020014303A publication Critical patent/MX2020014303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente descripción se refiere a inhibidores de la familia CBP/p300 de bromodominios. Los compuestos pueden ser útiles en el tratamiento de una enfermedad o trastorno asociado con la inhibición de la familia CBP/p300 de bromodominios. Por ejemplo, la descripción se refiere a compuestos y composiciones para la inhibición de la familia de CBP/p300 de bromodominios, métodos para tratar, prevenir o mejorar enfermedades o trastornos asociados con la inhibición de la familia de CBP/p300 de bromodominios y métodos de síntesis de estos compuestos.
MX2020014303A 2018-06-29 2019-06-28 Inhibición de la proteína de union a creb (cbp). MX2020014303A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
US201962819490P 2019-03-15 2019-03-15
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)

Publications (1)

Publication Number Publication Date
MX2020014303A true MX2020014303A (es) 2021-03-25

Family

ID=68987627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014303A MX2020014303A (es) 2018-06-29 2019-06-28 Inhibición de la proteína de union a creb (cbp).

Country Status (24)

Country Link
US (3) US10870648B2 (es)
EP (1) EP3998266A1 (es)
JP (3) JP6781806B2 (es)
KR (1) KR20210025631A (es)
CN (2) CN112513038B (es)
AU (2) AU2019295790B2 (es)
BR (1) BR112020026783A2 (es)
CA (1) CA3105099A1 (es)
CY (1) CY1124762T1 (es)
DK (1) DK3587418T3 (es)
ES (1) ES2900105T3 (es)
HR (1) HRP20211698T1 (es)
HU (1) HUE056885T2 (es)
IL (1) IL279734A (es)
LT (1) LT3587418T (es)
MA (1) MA50675B1 (es)
MX (1) MX2020014303A (es)
PL (1) PL3587418T3 (es)
PT (1) PT3587418T (es)
RS (1) RS62732B1 (es)
SG (1) SG11202012767UA (es)
SI (1) SI3587418T1 (es)
WO (1) WO2020006483A1 (es)
ZA (1) ZA202100509B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020026783A2 (pt) * 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Inibição da proteína de ligação creb (cbp)
CN113784967A (zh) * 2019-03-15 2021-12-10 福马治疗股份有限公司 用于治疗雄激素受体阳性形式的癌症的组合物和方法
WO2021260109A1 (en) 2020-06-25 2021-12-30 Tolremo Therapeutics Ag A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC
KR20230028798A (ko) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
JP5355838B2 (ja) 2000-11-20 2013-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな光異性化可能な化合物
CA2463136A1 (en) 2001-10-17 2003-04-24 Raymond Andersen Ship 1 modulators
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (es) 2003-11-13 2008-10-06
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP1968950A4 (en) 2005-12-19 2010-04-28 Genentech Inc PYRIMIDINKINASEINHIBITOREN
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CN101489544A (zh) 2006-05-09 2009-07-22 海玛奎斯特医药公司 治疗血液病的方法
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
IN2014MN02330A (es) 2007-06-21 2015-08-14 Wistar Inst
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
JP5223864B2 (ja) 2007-06-27 2013-06-26 大正製薬株式会社 １１β−ＨＳＤ１阻害活性を有する化合物
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
HUE043569T2 (hu) 2008-06-16 2019-08-28 Univ Tennessee Res Found Vegyületek rák kezelésére
US8604030B2 (en) * 2009-03-27 2013-12-10 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical containing same
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
SG175045A1 (en) 2009-04-15 2011-11-28 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
CN102459248A (zh) 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
KR20120130777A (ko) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
NZ603789A (en) * 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
CA2827392A1 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
WO2014045305A1 (en) 2012-09-21 2014-03-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
PT3010503T (pt) 2013-06-21 2020-06-16 Zenith Epigenetics Corp Novos inibidores bicíclicos de bromodomínios
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
EP3071203B1 (en) 2013-11-18 2020-12-23 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
JP6771464B2 (ja) * 2014-11-27 2020-10-21 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
US10435402B2 (en) 2015-01-08 2019-10-08 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
DK3681885T3 (da) * 2017-09-15 2024-04-15 Forma Therapeutics Inc Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
BR112020026783A2 (pt) * 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Inibição da proteína de ligação creb (cbp)

Also Published As

Publication number Publication date
JP2020128426A (ja) 2020-08-27
EP3998266A1 (en) 2022-05-18
MA50675A (fr) 2021-04-07
US11254674B2 (en) 2022-02-22
US20220162207A1 (en) 2022-05-26
AU2019295790A1 (en) 2021-01-28
JP2020002135A (ja) 2020-01-09
KR20210025631A (ko) 2021-03-09
SI3587418T1 (sl) 2022-03-31
BR112020026783A2 (pt) 2021-03-30
US10870648B2 (en) 2020-12-22
DK3587418T3 (da) 2021-10-11
HUE056885T2 (hu) 2022-03-28
PT3587418T (pt) 2021-12-02
AU2023226653A1 (en) 2023-09-21
ES2900105T3 (es) 2022-03-15
JP7017801B2 (ja) 2022-02-09
WO2020006483A1 (en) 2020-01-02
CN116178369A (zh) 2023-05-30
CA3105099A1 (en) 2020-01-02
IL279734A (en) 2021-03-01
PL3587418T3 (pl) 2022-02-21
JP2021042255A (ja) 2021-03-18
CN112513038A (zh) 2021-03-16
SG11202012767UA (en) 2021-01-28
RS62732B1 (sr) 2022-01-31
HRP20211698T1 (hr) 2022-02-18
JP6781806B2 (ja) 2020-11-04
ZA202100509B (en) 2022-12-21
US20200299295A1 (en) 2020-09-24
AU2019295790B2 (en) 2023-07-13
CN112513038B (zh) 2023-01-10
LT3587418T (lt) 2021-11-25
CY1124762T1 (el) 2022-07-22
MA50675B1 (fr) 2021-09-30
US20200002332A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
CR20210516A (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
MX2021013146A (es) Inhibidores de receptores del factor de crecimiento de fibroblastos (fgfr) y metodos de uso de los mismos.
PH12020552228A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2021002805A (es) Terapias de combinacion.
MX2022013417A (es) Inhibidores de fosfatidilinositol 3 cinasa (pi3k) alfa y metodos de uso de los mismos.
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
ATE424208T1 (de) Proteinkinaseinhibitoren
EA033237B1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022000845A (es) Compuestos inhibidores.
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
MX2023000332A (es) Heterociclos triciclicos.